CN108472344A - 用于针对人患者中的自身抗原的疫苗接种方法 - Google Patents

用于针对人患者中的自身抗原的疫苗接种方法 Download PDF

Info

Publication number
CN108472344A
CN108472344A CN201680064233.5A CN201680064233A CN108472344A CN 108472344 A CN108472344 A CN 108472344A CN 201680064233 A CN201680064233 A CN 201680064233A CN 108472344 A CN108472344 A CN 108472344A
Authority
CN
China
Prior art keywords
antigen
self
autoantigen
dose
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680064233.5A
Other languages
English (en)
Chinese (zh)
Inventor
G.加拉博瓦
S.施米德胡伯
A.施尼伯杰
A.冯博尼
D.温特
J.齐默曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AC Immune SA
Original Assignee
Affiris AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affiris AG filed Critical Affiris AG
Publication of CN108472344A publication Critical patent/CN108472344A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0007—Nervous system antigens; Prions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/627—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier characterised by the linker

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN201680064233.5A 2015-11-03 2016-11-02 用于针对人患者中的自身抗原的疫苗接种方法 Pending CN108472344A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15192794.4 2015-11-03
EP15192794 2015-11-03
PCT/EP2016/076372 WO2017076873A1 (en) 2015-11-03 2016-11-02 Method for vaccination against a self-antigen in a human patient

Publications (1)

Publication Number Publication Date
CN108472344A true CN108472344A (zh) 2018-08-31

Family

ID=54396782

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680064233.5A Pending CN108472344A (zh) 2015-11-03 2016-11-02 用于针对人患者中的自身抗原的疫苗接种方法

Country Status (10)

Country Link
US (1) US12290553B2 (enExample)
EP (1) EP3370761A1 (enExample)
JP (2) JP7378931B2 (enExample)
KR (1) KR102857456B1 (enExample)
CN (1) CN108472344A (enExample)
AU (1) AU2016348610B2 (enExample)
BR (1) BR112018008697A2 (enExample)
CA (1) CA3003943A1 (enExample)
RU (1) RU2734924C2 (enExample)
WO (1) WO2017076873A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102857456B1 (ko) * 2015-11-03 2025-09-08 에이씨 이뮨 에스에이 인간 환자에서 자가-항원에 대한 예방접종을 위한 방법
AR111760A1 (es) * 2017-05-19 2019-08-14 Novartis Ag Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
CN112533959A (zh) * 2018-05-22 2021-03-19 阿尔伯塔大学理事会 用于基于结构的淀粉样蛋白疾病疫苗和抗原的无害的、结构化的支架
CA3185563A1 (en) 2020-08-04 2022-02-10 Dorian WINTER Immunogenic compounds
KR102527616B1 (ko) 2021-03-18 2023-05-02 정성욱 항체 관련 정보를 제공하는 방법 및 디바이스
MX2024009485A (es) 2022-02-09 2024-08-14 Ac Immune Sa Vacunas terapeuticas anti-alfa-sinucleina.
WO2025172592A1 (en) 2024-02-15 2025-08-21 Ac Immune Sa Alpha synuclein therapeutic vaccine

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1713817A (zh) * 2002-10-23 2005-12-28 葛兰素史密丝克莱恩生物有限公司 抗疟疾的疫苗接种方法
WO2009103105A2 (en) * 2008-02-22 2009-08-27 Affiris Ag Mimotope
WO2011009152A1 (en) * 2009-07-23 2011-01-27 Affiris Ag Vaccine
CN102762206A (zh) * 2009-12-15 2012-10-31 诺华有限公司 免疫增强化合物的均匀悬液及其用途
WO2014033158A2 (en) * 2012-08-29 2014-03-06 Affiris Ag Vaccine
CN104427996A (zh) * 2012-05-01 2015-03-18 阿费里斯股份公司 组合物
CN104548089A (zh) * 2009-09-03 2015-04-29 辉瑞疫苗有限责任公司 Pcsk9疫苗

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT413945B (de) 2003-01-14 2006-07-15 Mattner Frank Dr Impfstoff für die alzheimer-krankheit
AT413946B (de) 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
AT508638B1 (de) 2009-08-21 2011-08-15 Affiris Ag Verwendung von peptiden und polypeptiden zur behandlung und/oder prävention von synukleinopathien
EP2666785A1 (en) 2012-05-23 2013-11-27 Affiris AG Complement component C5a-based vaccine
DK3110439T3 (da) 2014-02-28 2019-05-13 Affiris Ag Pcsk9-vacciner
KR102857456B1 (ko) 2015-11-03 2025-09-08 에이씨 이뮨 에스에이 인간 환자에서 자가-항원에 대한 예방접종을 위한 방법

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1713817A (zh) * 2002-10-23 2005-12-28 葛兰素史密丝克莱恩生物有限公司 抗疟疾的疫苗接种方法
US20110092434A1 (en) * 2008-02-22 2011-04-21 Affiris Ag Mimotopes of alpha-synuclein and vaccines thereof for the treatment of neurodegenerative disorders
WO2009103105A2 (en) * 2008-02-22 2009-08-27 Affiris Ag Mimotope
JP2011512363A (ja) * 2008-02-22 2011-04-21 アフィリス・アクチェンゲゼルシャフト 神経変性疾患治療のためのαシヌクレインのミモトープ及びそれらのワクチン
US20120269836A1 (en) * 2009-07-23 2012-10-25 Affiris Ag Vaccine
CN102573894A (zh) * 2009-07-23 2012-07-11 阿费里斯股份公司 疫苗
WO2011009152A1 (en) * 2009-07-23 2011-01-27 Affiris Ag Vaccine
JP2012533572A (ja) * 2009-07-23 2012-12-27 アフィリス・アクチェンゲゼルシャフト ワクチン
CN104548089A (zh) * 2009-09-03 2015-04-29 辉瑞疫苗有限责任公司 Pcsk9疫苗
CN102762206A (zh) * 2009-12-15 2012-10-31 诺华有限公司 免疫增强化合物的均匀悬液及其用途
CN104427996A (zh) * 2012-05-01 2015-03-18 阿费里斯股份公司 组合物
JP2015520739A (ja) * 2012-05-01 2015-07-23 アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ 組成物
WO2014033158A2 (en) * 2012-08-29 2014-03-06 Affiris Ag Vaccine
CN104685053A (zh) * 2012-08-29 2015-06-03 阿费里斯股份公司 Pcsk9肽疫苗
JP2015528453A (ja) * 2012-08-29 2015-09-28 アフィリス・アクチェンゲゼルシャフトＡｆｆｉｒｉｓ Ａｇ Ｐｃｓｋ９ペプチドワクチン

Non-Patent Citations (13)

* Cited by examiner, † Cited by third party
Title
AFFIRIS AG: "First Clinical Data of Therapeutic Parkinson"s Disease Vaccine Encourages Continued Development", 《HTTPS://WEB.ARCHIVE.ORG/WEB/20150505235928/HTTPS://WWW.PRNEWSWIRE.COM/NEWS-RELEASES/FIRST-CLINICAL-DATA-OF-THERAPEUTIC-PARKINSONS-DISEASE-VACCINE-ENCOURAGES-CONTINUED-DEVELOPMENT-269390241.HTML》 *
AFFIRIS AG: "Follow-up Study to Assess One Boost Immunization With AFFITOPE® PD01A With Regard to Safety and Clinical Activity (AFF008A)", 《CLINICALTRIALS.GOV》 *
AFFIRIS AG: "Tolerability and Safety of Subcutaneous Administration of Two Doses of AFFITOPE® PD01A in Early Parkinson"s Disease", 《CLINICALTRIALS.GOV》 *
ASHWINI SHETE等: "Is Prime Boost Strategy a Promising Approach in HIV Vaccine Development", 《JOURNAL OF AIDS & CLINICAL RESEARCH》 *
CLAIRE-ANNE SIEGRIST: "《Vaccination》", 31 December 2008, ELSEVIER *
GERGANA GALABOVA等: "Peptide-Based Anti-PCSK9 Vaccines – An Approach for Long-Term LDLc Management", 《PLOS ONE》 *
GISELA GONZALES等: "Therapeutic vaccination with epidermal growth factor(EGF) in advanced lung cancer: analysis of pooled data from three clinical trials", 《HUMAN VACCINES》 *
JEFFREY B. HALTER等: "《哈兹德老年医学第6版上卷》", 31 January 2015, 人民军医出版社 *
MARKUS MANDLER等: "Active immunization against alpha-synuclein ameliorates the degenerative pathology and prevents demyelination in a model of multiple system atrophy", 《MOLECULAR NEURODEGENERATION》 *
MARKUS MANDLER等: "Next-generation active immunization approach for synucleinopathies: implications for Parkinson"s disease clinical trials", 《ACTA NEUROPATHOLOGICA》 *
P. LANDRY等: "Inactivated hepatitis A vaccine booster given ≥24 months after the primary dose", 《VACCINE》 *
YANELYS MORERA等: "Antigen dose escalation study of a VEGF-based therapeutic cancer vaccine in non human primates", 《VACCINE》 *
雷朋等: "优化核酸疫苗对帕金森病小鼠纹状体神经末梢的免疫治疗作用", 《免疫学杂志》 *

Also Published As

Publication number Publication date
BR112018008697A2 (en) 2018-10-30
CA3003943A1 (en) 2017-05-11
US20190091306A1 (en) 2019-03-28
RU2734924C2 (ru) 2020-10-26
JP7628333B2 (ja) 2025-02-10
WO2017076873A1 (en) 2017-05-11
AU2016348610A1 (en) 2018-05-10
AU2016348610B2 (en) 2023-08-31
KR102857456B1 (ko) 2025-09-08
US12290553B2 (en) 2025-05-06
RU2018120009A3 (enExample) 2020-04-23
KR20180079406A (ko) 2018-07-10
RU2018120009A (ru) 2019-12-04
EP3370761A1 (en) 2018-09-12
JP7378931B2 (ja) 2023-11-14
JP2023175708A (ja) 2023-12-12
JP2018532782A (ja) 2018-11-08

Similar Documents

Publication Publication Date Title
JP7628333B2 (ja) ヒト患者における自己抗原に対するワクチン接種法
Wang et al. UB-311, a novel UBITh® amyloid β peptide vaccine for mild Alzheimer's disease
US10005825B2 (en) Compositions and methods related to diseases associated with deposits of amyloid, tau, and alpha-synuclein
US11419924B2 (en) Immunotherapeutic compositions for the treatment of Alzheimer's disease
JP2019196397A (ja) アルツハイマー型認知症の予防用及び免疫療法用ペプチドワクチン
KR20110036809A (ko) 파킨슨병과 관련된 증상을 치료하기 위한 화합물
CN104427996A (zh) 组合物
CN104411328A (zh) 组合物
Maier et al. Modulation of the humoral and cellular immune response in Aβ immunotherapy by the adjuvants monophosphoryl lipid A (MPL), cholera toxin B subunit (CTB) and E. coli enterotoxin LT (R192G)
JP2023536497A (ja) 免疫原性化合物
Ding et al. Active immunization with the peptide epitope vaccine Aβ3-10-KLH induces a Th2-polarized anti-Aβ antibody response and decreases amyloid plaques in APP/PS1 transgenic mice
Myagkova et al. Vaccines for substance abuse treatment: New approaches in the immunotherapy of addictions
EA048154B1 (ru) Иммуногенные соединения
HK40087814A (zh) 免疫原性化合物
US20220218806A1 (en) Peptides and conjugates for treatment of arthritis
US20190184013A1 (en) Compositions for selective humoral responses and methods of use thereof
TW201938585A (zh) 阿茲海默氏症之新abeta變體、測定、方法及治療
NZ744411A (en) Amyloid conjugate and uses and methods thereof
NZ744411B2 (en) Amyloid conjugate and uses and methods thereof
JP2011201902A (ja) 可溶性Ａ−βに対する抗体を生成させるための能動免疫

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20211124

Address after: Lausanne

Applicant after: AC Immune S.A.

Address before: Austria Vienna

Applicant before: AFFIRIS AG

TA01 Transfer of patent application right
CB02 Change of applicant information

Address after: Lausanne

Applicant after: Aisi immunization Co.,Ltd.

Address before: Lausanne

Applicant before: AC Immune S.A.

CB02 Change of applicant information